Erectile dysfunction in men with cardiovascular disease: the possibility of prevention with Eromax

DOI: https://doi.org/10.29296/25877305-2023-07-06
Issue: 
7
Year: 
2023

Professor D. Dedov, MD
Tver State Medical University,
Tver Regional Clinical Cardiology Centre

Objective. To analyze research of the problem of occurrence and prevention of erectile dysfunction in men with cardiovascular diseases. Material and methods. Analysis of the literature data reflecting investigations of the problem of erectile dysfunction in men with cardiovascular diseases was carried out. Results and discussion. Erectile dysfunction is a fairly common disease in men. It is manifested by an inability to achieve or maintain an erection, sufficient to have sexual intercourse for more than 3 months. In the Russian Federation, erectile dysfunction occurs in 48.9% of men aged 20–77 years. Erectile dysfunction and cardiovascular disease share common pathogenetic mechanisms. A combination of these pathologies is often seen in the same patient. Age and cardiovascular disease are associated with an increased risk of erectile dysfunction. Conclusion. The Russian drug Eromax (Parafarm company) is able to increase sexual desire, improve the duration of an erection and mood, stabilize the vegetative system and may be recommended for the prevention of erectile dysfunction and for improving the quality in men with cardiovascular diseases, taking into consideration the existing comorbid pathology and an individual approach to each patient.
Keywords: 
cardiology
erectile dysfunction
erection
cardiovascular diseases
Eromax
Parafarm company.

References: 
  1. Клинические рекомендации Министерства здравоохранения Российской Федерации. Эректильная дисфункция. 2022–2023 (21.12.2021). 20 c. [Clinical recommendations of the Ministry of Health of the Russian Federation. Erectile dysfunction. 2022–2023 (21.12.2021). 20 p. (in Russ.)] URL: https://cr.minzdrav.gov.ru/schema/15_2
  2. Shamloul R., Ghanem H. Erectile dysfunction. Lancet. 2013; 381 (9861): 153–65. DOI: 10.1016/S0140-6736(12)60520-0
  3. Gandaglia G., Briganti A., Jackson G. et al. A systematic review of the association between erectile dysfunction and cardiovascular disease. Eur Urol. 2014; 65 (5): 968–78. DOI: 10.1016/j.eururo.2013.08.023
  4. Shah N.P., Cainzos-Achirica M., Feldman D.I. et al. Cardiovascular Disease Prevention in Men with Vascular Erectile Dysfunction: The View of the Preventive Cardiologist. Am J Med. 2016; 129 (3): 251–9. DOI: 10.1016/j.amjmed.2015.08.038
  5. Jackson G. Erectile dysfunction and coronary disease: evaluating the link. Maturitas. 2012; 72 (3): 263–4. DOI: 10.1016/j.maturitas.2012.03.012
  6. Al-Daydamony M.M., Shawky A., Tharwat A. Erectile dysfunction severity as a predictor of left main and/or three-vessel disease in acute coronary syndrome patients. Indian Heart J. 2018; 70 (3): S56–S59. DOI: 10.1016/j.ihj.2018.05.006
  7. Sai Ravi Shanker A., Phanikrishna B., Bhaktha Vatsala Reddy C. Association between erectile dysfunction and coronary artery disease and its severity. Indian Heart J. 2013; 65 (2): 180–6. DOI: 10.1016/j.ihj.2013.02.013
  8. Leye M.M., Faye A., Ka O. et al. Cardiovascular risk factors associated with erectile dysfunction in the region of Dakar, Senegal. Rev Epidemiol Sante Publique. 2016; 64 (3): 195–200. DOI: 10.1016/j.respe.2015.12.018
  9. Pauker-Sharon Y., Arbel Y., Finkelstein A. et al. Cardiovascular risk factors in men with ischemic heart disease and erectile dysfunction. Urology. 2013; 82 (2): 377–80. DOI: 10.1016/j.urology.2013.03.034
  10. Mahamat-Azaki O., Ekou A., Soya E. et al. Prevalence and characteristics of erectile dysfunction in coronary patients in Abidjan Heart Institute of Côte d'ivoire. Ann Cardiol Angeiol (Paris). 2023; 72 (2): 101575. DOI: 10.1016/j.ancard.2022.11.010
  11. Desai M., Naik G., Kamat U.S. et al. Concurrence of erectile dysfunction and coronary artery disease among patients undergoing coronary angiography at a tertiary Medical College Hospital in Goa. Indian Heart J. 2020; 72 (2): 123–5. DOI: 10.1016/j.ihj.2020.03.007
  12. Lemogne C., Ledru F., Bonierbale M. et al. Erectile dysfunction and depressive mood in men with coronary heart disease. Int J Cardiol. 2010; 138 (3): 277–80. DOI: 10.1016/j.ijcard.2008.08.017
  13. Manalo T.A., Biermann H.D., Patil D.H. et al. The Temporal Association of Depression and Anxiety in Young Men with Erectile Dysfunction. J Sex Med. 2022; 19 (2): 201–6. DOI: 10.1016/j.jsxm.2021.11.011
  14. Mulat B., Arbel Y., Mashav N. et al. Depressive symptoms and erectile dysfunction in men with coronary artery disease. Urology. 2010; 75 (1): 104–7. DOI: 10.1016/j.urology.2009.09.041
  15. Fadzil M.A., Sidi H., Ismail Z. et al. Socio-demographic and psychosocial correlates of erectile dysfunction among hypertensive patients. Compr Psychiatry. 2014; 55 (1): S23–8. DOI: 10.1016/j.comppsych.2012.12.024
  16. Mittawae B., El-Nashaar A.R., Fouda A. et al. Incidence of erectile dysfunction in 800 hypertensive patients: a multicenter Egyptian national study. Urology. 2006; 67 (3): 575–8. DOI: 10.1016/j.urology.2005.09.040
  17. Kałka D., Gebala J., Rusiecki L. et al. Relation of Postexercise Reduction of Arterial Blood Pressure and Erectile Dysfunction in Patients with Coronary Heart Disease. Am J Cardiol. 2018; 122 (2): 229–34. DOI: 10.1016/j.amjcard.2018.03.368
  18. Manolis A., Doumas M., Ferri C. et al. Erectile dysfunction and adherence to antihypertensive therapy: Focus on β-blockers. Eur J Intern Med. 2020; 81: 1–6. DOI: 10.1016/j.ejim.2020.07.009
  19. Wright L.N., Moghalu O.I., Das R. et al. Erectile Dysfunction and Treatment: An Analysis of Associated Chronic Health Conditions. Urology. 2021; 157: 148–54. DOI: 10.1016/j.urology.2021.08.009
  20. Farmakis I.T., Pyrgidis N., Doundoulakis I. et al. Effects of Major Antihypertensive Drug Classes on Erectile Function: a Network Meta-analysis. Cardiovasc Drugs Ther. 2022; 36 (5): 903–14. DOI: 10.1007/s10557-021-07197-9
  21. Omland T., Randby A., Hrubos-Strøm H. et al. Relation of Erectile Dysfunction to Subclinical Myocardial Injury. Am J Cardiol. 2016; 118 (12): 1821–5. DOI: 10.1016/j.amjcard.2016.08.070
  22. Ryan J.G., Gajraj J. Erectile dysfunction and its association with metabolic syndrome and endothelial function among patients with type 2 diabetes mellitus. J Diabetes Complications. 2012; 26 (2): 141–7. DOI: 10.1016/j.jdiacomp.2011.12.001
  23. Gandaglia G., Briganti A., Montorsi P. et al. Diagnostic and Therapeutic Implications of Erectile Dysfunction in Patients with Cardiovascular Disease. Eur Urol. 2016; 70 (2): 219–22. DOI: 10.1016/j.eururo.2016.01.054
  24. Barrett-Connor E. Heart disease risk factors predict erectile dysfunction 25 years later (the Rancho Bernardo Study). Am J Cardiol. 2005; 96 (12B): 3M–7M. DOI: 10.1016/j.amjcard.2005.07.012
  25. Seidu S., Cebrián A., Kunutsor S.K. et al. Erectile dysfunction, phosphodiesterase-5 inhibitor use and risk of cardiovascular disease and mortality in people with diabetes: A systematic review and meta-analysis. Prim Care Diabetes. 2022; 16 (5): 601–13. DOI: 10.1016/j.pcd.2022.09.004
  26. Pellegrino F., Sjoberg D.D., Tin A.L. et al. Relationship Between Age, Comorbidity, and the Prevalence of Erectile Dysfunction. Eur Urol Focus. 2023; 9 (1): 162–7. DOI: 10.1016/j.euf.2022.08.006
  27. Garcia-Cruz E., Carrión A., Ajami T. et al. The Patient's Comorbidity Burden Correlates with the Erectile Dysfunction Severity. Actas Urol Esp (Engl Ed). 2018; 42 (1): 57–63. DOI: 10.1016/j.acuro.2017.03.011
  28. Петрова Е., Елистратов Д. Терапевтическая коррекция эректильной дисфункции и тревожно-депрессивных расстройств у пациентов с артериальной гипертензией. Врач. 2016; 4: 78–81 [Petrova E., Elistratov D. Therapeutic correction of erectile dysfunction and anxiety-depressive disorders in patients with arterial hypertension. Vrach. 2016; 4: 78–81 (in Russ.)].
  29. Каюмова М., Горбунова Т., Гакова Е. и др. Частота ассоциации соматических факторов риска ИБС и личностной тревожности у мужчин. Врач. 2018; 29 (4): 40–3 [Kayumova M., Gorbunova T., Gakova E. et al. Frequency of association of somatic risk factors for coronary heart disease and trait anxiety in men. Vrach. 2018; 29 (4): 40–3. (in Russ.)]. DOI: 10.29296/25877305-2018-04-07
  30. Петрова Е., Герцог Н., Баранова Г. и др. Взаимно потенцирующая триада: депрессия, эректильная дисфункция и сердечно-сосудистая патология у мужчин. Врач. 2019; 30 (12): 3–6 [Petrova E., Herzog N., Baranova G. et al. Mutually reinforcing triad: depression, erectile dysfunction and cardiovascular pathology in men. Vrach. 2019; 30 (12): 3–6 (in Russ.)]. DOI: 10.29296/25877305-2019-12-01
  31. Гацких И.В., Потупчик Т.В., Шалда Т.П. Когнитивные расстройства у пациентов с ожирением (пилотное исследование). Возможности коррекции. Врач. 2023; 34 (3): 73–9 [Gatskikh I., Potupchik T., Shalda T. Cognitive impairment in obese patients: a pilot study. Correction possibilities. Vrach. 2023; 34 (3): 73–9 (in Russ.)]. DOI: 10.29296/25877305-2023-03-16
  32. Дедов Д., Мукаилов Н., Евтюхин И. Качество жизни и прогноз у больных АГ и ИБС с фибрилляцией предсердий. Врач. 2013; 7: 72–4 [Dedov D., Mukailov N., Evtyukhin I. Quality of life and prognosis in patients with arterial hypertension and coronary heart disease with atrial fibrillation. Vrach. 2013; 7: 72–74. (in Russ.)].
  33. Петрова Е.В., Шутов А.М. Эректильная дисфункция и тревожно-депрессивное расстройство при артериальной гипертензии: патогенетические связи и подходы к лечению. Международный журнал сердца и сосудистых заболеваний. 2017; 5 (14): 11–8 [Petrova E.V., Shutov A.M. Triad of erectile dysfunction, anxiety and depressive disorders, arterial hypertension: pathogenetic communication and approaches to treatment. Mezhdunarodnyi Zhurnal Serdtsa I Sosudistykh Zabolevanii. 2017; 5 (14): 11–8 (in Russ.)].
  34. Петрова Е., Шутов А., Струков В. Патогенетические связи эректильной дисфункции и тревожно-депрессивных расстройств при артериальной гипертензии. Врач. 2018; 29 (7): 72–8 [Petrova E., Shutov A., Strukov V. Pathogenetic communication of erectile dysfunction, anxiety and depressive disorders in hypertension. Vrach. 2018; 29 (7): 72–8 (in Russ.)]. DOI: 10.29296/25877305-2018-07-17
  35. Митрофанов Д.В., Будникова Н.В., Бурмистрова Л.А. Гормоны трутневого расплода медоносных пчел разного возраста. Пчеловодство. 2015; 7: 58–9 [Mitrofanov D.V., Budnikova N.V., Burmistrova L.A. Hormones of drone brood of honey bees of different ages. Pchelovodstvo. 2015; 7: 58–9 (in Russ.)].
  36. Биохимия: учебник. Под ред. Е.С. Северина. 5-е изд., испр. и доп. М.: ГЭОТАР-Медиа, 2014; 768 с. [Biochemistry: textbook. Ed . E.S. Severin. 5th ed., corrected and supplemented. M.: GEOTAR-Media, 2014; 768 p. (in Russ.)].
  37. Бурмистрова Л.А. Физико-химический анализ и биохимическая оценка биологической активности трутневого расплода. Дис. … канд. биол. наук. Рыбное, 1999 [Burmistrova L.A. Physico-chemical analysis and biochemical assessment of biological activity of drone brood. Dis. ... cand. biol. sciences. Rybnoe, 1999 (in Russ.)].
  38. Митрофанов Д.В., Будникова Н.В., Брандорф А.З. Применение трутневого расплода в рациональном питании и апитерапии. Аграрная наука Евро-Северо-Востока. 2021; 22 (2): 188–203 [Mitrofanov D.V., Budnikova N.V., Brandorf A.Z. Application of drone brood in rational nutrition and apitherapy. Agricultural Science Euro-North-East. 2021; 22 (2): 188–203 (in Russ.)]. DOI: 10.30766/2072-9081.2021.22.2.188-203
  39. Cheah Y., Yang W. Functions of essential nutrition for high quality spermatogenesis. Advances in Bioscience and Biotechnology. 2011; 2 (4): 182–97. DOI: 10.4236/abb.2011.24029
  40. Palmer K.M.J., Ferringe A.G., Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature. 1987; 327 (6122): 524–6. DOI: 10.1038/327524a0